Company: TELO
Filing Date: 2025-11-12
Form Type: 8-K
Source: 0001493152-25-021712
Chunk: 1

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-12
Form: 8-K
Item: Item 8.01
Chunk 1
---
 the Company’s ongoing pre-clinical research focused on metal-ion balance, oxidative stress, and epigenetic enzyme
dynamics

SIGNATURES

Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

                         TELOMIR                                       
  Dated:                 By:                        /s/                
                         Name:                      Erez               
                         Title:                     Chief